Browse the evidence

Leptin resistance, caused by defects in blood-brain barrier transport or intracellular signaling (e.g., SOCS3), is the primary driver of common obesity, whereas absolute leptin deficiency is rare.

In common obesity, your body produces plenty of leptin (the satiety hormone), but your brain stops listening to it. This 'leptin resistance' is a key biological barrier to weight loss.

Chronic low-grade inflammation (inflammaging) drives vascular aging by promoting oxidative stress, endothelial dysfunction, and atherosclerosis through the upregulation of cytokines like TNF-alpha and NF-kB activation.

Chronic, low-grade inflammation is a major driver of heart disease in older adults. It damages blood vessels by promoting oxidative stress and cell death. Managing inflammation through lifestyle factors is a key strategy for preventing age-related vascular disease.

In obese patients with type 2 diabetes, untreated obstructive sleep apnea (OSA) progresses rapidly, with AHI increasing by approximately 4 events per hour over one year even without weight gain.

If you have type 2 diabetes and sleep apnea, do not assume that staying at your current weight means your sleep apnea will stay stable. Without treatment or weight loss, your sleep apnea severity tends to worsen by about 4 events per hour each year. Early intervention is crucial to prevent this progression.

Roux-en-Y gastric bypass (RYGB) resolves type 2 diabetes mellitus in approximately 83% of cases, often within days of surgery, through mechanisms that improve insulin sensitivity and secretion independently of immediate weight loss.

If you have type 2 diabetes and undergo Roux-en-Y gastric bypass, expect a high likelihood of remission (approx. 83%), often occurring within days of surgery, long before you lose significant weight. This is driven by hormonal changes that improve insulin sensitivity and secretion. You may be able to discontinue diabetes medications quickly, but this requires close medical supervision.

Dietary intake of choline and L-carnitine leads to the gut microbial production of Trimethylamine (TMA), which is converted by host liver enzymes (FMO3) into Trimethylamine N-oxide (TMAO).

Eating foods rich in choline (eggs, meat) and carnitine (red meat) provides the raw materials for your gut bacteria to create TMA, which your liver turns into TMAO. This process is the primary way diet influences TMAO levels.

Familial Combined Hyperlipidemia (FCHL) is a common genetic subtype of the metabolic syndrome characterized by disproportionately elevated Apo B levels, which significantly increases the risk of premature coronary artery disease compared to the metabolic syndrome alone.

If you have metabolic syndrome, ask your doctor to check your Apo B levels. If they are high, you may have Familial Combined Hyperlipidemia (FCHL), a genetic condition that puts you at much higher risk for heart disease than metabolic syndrome alone. This diagnosis is crucial because it often requires more aggressive treatment, such as lipid-lowering therapy, to prevent heart attacks.

Measuring Apolipoprotein B (Apo B) is a superior predictor of cardiovascular risk compared to standard LDL cholesterol in patients with the metabolic syndrome, as it accurately reflects the total number of atherogenic particles.

Standard cholesterol tests measure the amount of cholesterol in LDL particles, not the number of particles. In metabolic syndrome, particles are small and dense, carrying less cholesterol but causing more damage. Asking for an Apo B test gives a more accurate count of these dangerous particles, helping your doctor decide if you need stronger medication to protect your heart.

Leptin resistance, a primary risk factor for obesity, results from impaired leptin transport across the blood-brain barrier, defective LEPRb signaling (via SOCS3 and PTP1B), and disrupted hypothalamic neurocircuitry.

Obesity is not just about calories; it involves a broken hormonal signal (leptin) that fails to tell your brain to stop eating and burn fat. This failure happens due to transport issues, receptor signaling blocks (like SOCS3), and neural circuit changes. Treating obesity requires addressing these biological resistance mechanisms, not just willpower.

Leptin regulates energy balance primarily by acting on the hypothalamus (specifically ARC, VMH, PVH) to activate LEPRb, which triggers downstream pathways (STAT3, PI3K, MAPK) to suppress appetite and increase energy expenditure.

Your brain's hypothalamus is the control center for weight, using leptin signals to decide how much to eat and burn. This process relies on specific receptors (LEPRb) and signaling pathways (STAT3, PI3K) within the brain.

Obstructive Sleep Apnea is causally linked to the development of systemic hypertension, with worsening AHI independently associated with an increasing risk of new hypertension, even in mild cases.

Even mild sleep apnea can silently raise your risk of developing high blood pressure. If you have risk factors like obesity or snoring, getting screened for sleep apnea is important for your long-term heart health, regardless of whether you feel tired during the day.

Adiposity signals (leptin and insulin) decline disproportionately to fat mass loss because smaller adipocytes secrete less leptin and are more insulin-sensitive, creating a persistent 'energy depletion' signal even when fat mass is stable.

Your body's 'fuel gauge' (leptin/insulin) reads lower than your actual fat mass suggests because your fat cells have shrunk. This tricks your brain into thinking you are starving, driving hunger and conserving energy. This is a normal physiological response to weight loss.

Total testosterone levels remain relatively stable until approximately age 55 in healthy nonobese men, after which they decline rapidly, while free testosterone declines linearly from a younger age.

For healthy men, Total Testosterone stays stable until about 55. If you are younger, low Total T might not be 'just aging.' However, Free Testosterone starts dropping earlier, so symptoms may appear before Total T drops significantly.

Estrogen directs fat distribution to subcutaneous gluteo-femoral depots in premenopausal women, which is protective against cardiometabolic risk, whereas estrogen deficiency (menopause) shifts distribution to visceral fat, increasing risk.

For women, where fat is stored matters more than total fat. Estrogen protects by storing fat in hips/thighs. After menopause, estrogen drops, and fat moves to the belly, increasing health risks. Managing visceral fat through diet and exercise is critical post-menopause.

Obesity results from a loss of homeostatic energy balance regulation driven by evolutionary mismatch and peripheral signals (leptin/insulin) failing to inhibit orexigenic pathways (NPY/AgRP) due to resistance mechanisms.

Your body has a biological defense against weight loss involving hormones like leptin and neuropeptides like NPY. In obesity, these signals often fail (resistance), making it harder to lose weight through willpower alone. Understanding this helps shift the focus from 'eating less' to addressing the underlying hormonal signaling and environmental factors.

Rare and low-frequency coding genetic variants in genes such as MC4R, GIPR, and KSR2 are significantly associated with Body Mass Index (BMI), with effect sizes approximately ten times larger than those of common variants.

Your genetics play a role in your weight, but for most people, common lifestyle factors (diet, activity) are far more impactful than rare genetic mutations. If you have a known high-impact mutation like MC4R p.Tyr35Ter, you may need more aggressive or specialized medical interventions, but for the general population, focusing on energy balance remains the most effective strategy.

Catecholamines (adrenaline and noradrenaline) stimulate lipolysis by binding to beta-adrenergic receptors, increasing cAMP, and activating Protein Kinase A (PKA) to phosphorylate Hormone-Sensitive Lipase (HSL) and Perilipin.

Physical activity and stress increase catecholamines, which directly trigger fat breakdown. This is the body's primary mechanism for mobilizing energy during exercise or fasting. The process involves breaking down triglycerides into fatty acids and glycerol for use by other organs.

GLP-1 receptor agonists and DPP-4 inhibitors both have a low risk of hypoglycemia when used as monotherapy due to their glucose-dependent mechanism of action.

Both GLP-1 injections and DPP-4 inhibitor pills are safe in terms of hypoglycemia risk when taken alone. They only work to lower blood sugar when it is elevated, unlike insulin or sulphonylureas which can cause dangerous lows if you skip a meal.

Systemic and hepatic insulin resistance is the central pathophysiological mechanism driving the development and progression of metabolic dysfunction-associated fatty liver disease (MAFLD).

Focus on improving insulin sensitivity through weight management, physical activity, and dietary quality. Since insulin resistance is the root cause of MAFLD, interventions that lower insulin levels and improve glucose handling (like exercise and reducing refined carbohydrates) are the most effective way to prevent or reverse liver fat accumulation.

Insulin resistance in adipose tissue leads to increased free fatty acid (FFA) release, which drives hepatic fat accumulation and inflammation.

Reducing visceral fat through caloric deficit and exercise improves adipose tissue insulin sensitivity, thereby reducing the flood of FFAs to the liver and lowering liver fat.

Ghrelin is the primary gastric hormone responsible for stimulating appetite (orexigenic effect) by crossing the blood-brain barrier and signaling via vagal afferents, while leptin (primarily from adipose tissue, some from stomach) acts as an anorexigenic signal.

Ghrelin is your stomach's 'hunger hormone,' which rises before meals to stimulate appetite. While it plays a key role, simply trying to block it has not been an effective weight loss strategy so far. Appetite is regulated by a complex interplay of hormones (ghrelin, leptin, CCK, GLP-1) and neural signals.

Genetic variants associated with morningness (chronotype) and sleep duration are located near genes regulating circadian rhythms (RGS16, PER2) and photoreception (INADL, HTR6), indicating a biological basis for individual differences in sleep timing.

Your tendency to be a 'morning lark' or 'night owl' is largely determined by your genetics, specifically genes like RGS16 and PER2 that regulate your internal clock. Instead of fighting this predisposition, try to align your work and sleep schedules with your natural chronotype to improve sleep quality and metabolic health.

Genetic variants near the VRK2 gene are associated with shorter sleep duration, with each allele associated with approximately 1.6 to 2.0 minutes less sleep.

Genetic variants near the VRK2 gene are associated with slightly shorter sleep duration (1.6-2.0 minutes less per allele). While this is a statistically significant finding, the effect size is small and likely has minimal practical impact on an individual's total sleep time.

Obesity is a complex, heritable disorder resulting from the interplay of genetic susceptibility, epigenetics, metagenomics, and environmental factors, rather than solely lifestyle choices.

Recognize that obesity is a biological condition influenced by your genetics and environment, not just a failure of willpower. This understanding can reduce stigma and guide you toward evidence-based treatments, such as medications or surgeries, which may be necessary for those with specific genetic predispositions.

Bariatric/metabolic surgery induces rapid type 2 diabetes remission through weight-independent mechanisms, primarily involving altered gut hormone secretion (GLP-1, PYY), bile acid metabolism, and intestinal glucose disposal, occurring before significant weight loss.

For individuals with T2DM, bariatric surgery offers a potent, rapid improvement in blood sugar control that is driven by hormonal and metabolic changes in the gut, not just weight loss. This makes it a highly effective treatment for eligible candidates, particularly those who have not achieved remission through lifestyle changes alone. However, it is not suitable for everyone, especially those with long-standing diabetes and depleted insulin production.